AstraZeneca said on Tuesday that it will supply the U.S. government with an additional 500,000 doses of its experimental, long-acting antibody-based Covid-19 combination treatment that aims to protect those who aren’t able to be vaccinated.
The $205 million agreement to supply the treatment—called AZD7442—builds on a deal the Anglo-Swedish drug manufacturer struck last year with the Department of Health and Human Services and the Department of Defense (DoD).
Read:AstraZeneca advances Covid-19 antibody combo
Under that deal, announced in October, the U.S. invested $486 million for the development and supply of 100,000 doses of AZD7442, with an option to acquire up to an additional one million doses in 2021.
has a separate agreement to supply the DoD with